
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
Astria Therapeutics Inc. is positioned positively due to the promising preclinical results of its product candidates, particularly STAR-0310, which demonstrated favorable tolerability without adverse events typically associated with treatment, suggesting potential for enhanced efficacy compared to existing therapies. The merger with BioCryst has been viewed as a validation of Astria's strategy, expected to yield synergistic benefits that can enhance operating profits starting from the first full year following the launch of navenibart. Furthermore, Astria is anticipated to capitalize on a large commercial market opportunity, with expectations of significant news flow that could facilitate pipeline expansion and strategic growth initiatives.
Bears say
The financial outlook for Astria Therapeutics Inc is negatively impacted by several critical factors, notably the risk of failed or inconclusive clinical trials for its product candidates, STAR-0215 and STAR-0310. Additionally, the company's ability to secure adequate funding to support the progression of its drug development is uncertain, posing a significant threat to its operational continuity. Furthermore, risks regarding the completion of any acquisition and potential competition from other bidders may further complicate the company's valuation and hinder the achievement of clinical milestones necessary for financial stability.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares